Patents by Inventor Fraser Welsh

Fraser Welsh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS AND METHODS FOR TREATING PAIN
    Publication number: 20240026036
    Abstract: The disclosure provides novel methods and dosage regimens for use in treating or preventing pain, wherein the binding molecule comprises an NGF antagonist domain and a TNF? antagonist domain, wherein the NGF antagonist domain is an anti-NGF antibody or an antigen-binding fragment thereof and wherein the TNF? antagonist domain comprises a soluble TNF? binding fragment of TNFR.
    Type: Application
    Filed: September 27, 2021
    Publication date: January 25, 2024
    Inventors: FRASER WELSH, THARANI CHESSELL, KEITH TAN, THOR OSTENFELD, RICHARD JENKINS
  • ANTIBODIES TO AMYLOID BETA
    Publication number: 20220251181
    Abstract: Antibody for human amyloid beta. Antibody selectively binds human amyloid beta 42 peptide over human amyloid beta 40 peptide. Antibodies specific for amyloid beta 42 as therapeutic agents for binding amyloid beta 42 peptide and treating conditions associated with amyloidosis, such as Alzheimer's disease.
    Type: Application
    Filed: February 16, 2022
    Publication date: August 11, 2022
    Inventors: Maria Groves, Suzanne Gustavsson, Kina Höglund, Chris Lloyd, Adrian Nickson, Camilla Niva, Sylvia Simon, David Lowne, Fraser Welsh, Per-Ola Freskgard
  • Antibodies to amyloid beta
    Patent number: 11286297
    Abstract: Antibody for human amyloid beta. Antibody selectively binds human amyloid beta 42 peptide over human amyloid beta 40 peptide. Antibodies specific for amyloid beta 42 as therapeutic agents for binding amyloid beta 42 peptide and treating conditions associated with amyloidosis, such as Alzheimer's disease.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: March 29, 2022
    Assignee: MEDIMMUNE LIMITED
    Inventors: Maria Groves, Suzanne Gustavsson, Kina Höglund, Chris Lloyd, Adrian Nickson, Camilla Niva, Sylvia Simon, David Lowne, Fraser Welsh, Per-Ola Freskgärd
  • COMPOUNDS AND METHODS FOR TREATING PAIN
    Publication number: 20210009671
    Abstract: This disclosure provides novel methods and dosage regimens for use in treating pain with a binding molecule comprising comprising an NGF antagonist domain and a TNF? antagonist domain; wherein the NGF antagonist domain is an anti-NGF antibody, or antigen-binding fragment thereof; and wherein the TNF? antagonist domain comprises a soluble, TNF?-binding fragment of a TNFR.
    Type: Application
    Filed: May 7, 2020
    Publication date: January 14, 2021
    Inventor: Fraser Welsh
  • ANTIBODIES TO AMYLOID BETA
    Publication number: 20210009665
    Abstract: Antibody for human amyloid beta. Antibody selectively binds human amyloid beta 42 peptide over human amyloid beta 40 peptide. Antibodies specific for amyloid beta 42 as therapeutic agents for binding amyloid beta 42 peptide and treating conditions associated with amyloidosis, such as Alzheimer's disease.
    Type: Application
    Filed: May 1, 2020
    Publication date: January 14, 2021
    Inventors: Maria Groves, Suzanne Gustavsson, Kina Höglund, Chris Lloyd, Adrian Nickson, Camilla Niva, Sylvia Simon, David Lowne, Fraser Welsh, Per-Ola Freskgärd
  • Antibodies to amyloid beta
    Patent number: 10662239
    Abstract: Antibody for human amyloid beta. Antibody selectively binds human amyloid beta 42 peptide over human amyloid beta 40 peptide. Antibodies specific for amyloid beta 42 as therapeutic agents for binding amyloid beta 42 peptide and treating conditions associated with amyloidosis, such as Alzheimer's disease.
    Type: Grant
    Filed: October 25, 2017
    Date of Patent: May 26, 2020
    Assignee: MedImmune Limited
    Inventors: Maria Groves, Suzanne Gustavsson, Kina Höglund, Chris Lloyd, Adrian Nickson, Camilla Niva, Sylvia Simon, David Lowne, Fraser Welsh, Per-Ola Freskgärd
  • ANTIBODIES TO AMYLOID BETA
    Publication number: 20180105585
    Abstract: Antibody for human amyloid beta. Antibody selectively binds human amyloid beta 42 peptide over human amyloid beta 40 peptide. Antibodies specific for amyloid beta 42 as therapeutic agents for binding amyloid beta 42 peptide and treating conditions associated with amyloidosis, such as Alzheimer's disease.
    Type: Application
    Filed: October 25, 2017
    Publication date: April 19, 2018
    Inventors: Maria Groves, Suzanne Gustavsson, Kina Höglund, Chris Lloyd, Adrian Nickson, Camilla Niva, Sylvia Simon, David Lowne, Fraser Welsh, Per-Ola Freskgärd
  • Antibodies to amyloid beta
    Patent number: 9834598
    Abstract: Antibody for human amyloid beta. Antibody selectively binds human amyloid beta 42 peptide over human amyloid beta 40 peptide. Antibodies specific for amyloid beta 42 as therapeutic agents for binding amyloid beta 42 peptide and treating conditions associated with amyloidosis, such as Alzheimer's disease.
    Type: Grant
    Filed: October 15, 2013
    Date of Patent: December 5, 2017
    Assignee: MedImmune Limited
    Inventors: Maria Groves, Suzanne Gustavsson, Kina Höglund, Chris Lloyd, Adrian Nickson, Camilla Niva, Sylvia Simon, David Lowne, Fraser Welsh, Per-Ola Freskgärd
  • Antibodies to IL-17A and uses thereof
    Patent number: 8865166
    Abstract: Binding members, especially antibody molecules, for interleukin 17 (IL-17). The binding members are useful for the treatment of disorders associated with interleukin 17 such as rheumatoid arthritis.
    Type: Grant
    Filed: June 22, 2007
    Date of Patent: October 21, 2014
    Assignee: MedImmune Limited
    Inventors: Duncan Cochrane, Caroline Russell, Matthew Sleeman, Fraser Welsh, Caroline Langham, Maurice Needham, Patrick Dufner
  • Specific Binding Members For Ngf
    Publication number: 20080107658
    Abstract: Specific binding members for Nerve Growth Factor (NGF), in particular anti-NGF antibody molecules, especially human antibody molecules, and especially those that neutralise NGF activity. Methods for using anti-NGF antibody molecules in diagnosis or treatment of NGF related disorders, including pain, asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, other diseases of airway inflammation, diabetic neuropathy, cardiac arrhythmias, HIV, arthritis, psoriasis and cancer.
    Type: Application
    Filed: January 24, 2006
    Publication date: May 8, 2008
    Inventors: Ruth Franks, Andrew Buchanan, Albert Thom, Fraser Welsh, Philip Bland-Ward, Matthew Sleeman, Carl Matthews, Celia Hart, Jon Hawkinson
  • COMPOUNDS
    Publication number: 20080044423
    Abstract: Binding members, especially antibody molecules, for interleukin 17 (IL-17). The binding members are useful for the treatment of disorders associated with interleukin 17 such as rheumatoid arthritis.
    Type: Application
    Filed: June 22, 2007
    Publication date: February 21, 2008
    Inventors: Duncan Cochrane, Caroline Russell, Matthew Sleeman, Fraser Welsh, Caroline Langham, Maurice Needham, Patrick Dufner